预约演示
更新于：2025-04-07
Ferric Maltol
麦芽醇铁
更新于：2025-04-07
概要
基本信息
非在研机构 |
最高研发阶段批准上市 |
首次获批日期 欧盟 (2016-02-18), |
最高研发阶段(中国)无进展 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C18H15FeO9 |
InChIKeyAHPWLYJHTFAWKI-UHFFFAOYSA-K |
CAS号33725-54-1 |
关联
21
项与 麦芽醇铁 相关的临床试验NCT05697211
A Pilot Study to Explore Safety, Tolerability and Efficacy of ORal IrON Supplementation with Ferric Maltol in Treating Iron Deficiency and Anaemia in Patients with Heart Failure
CTRI/2023/01/048725
A phase III, randomised, single blind, comparative safety, efficacy and cost effectiveness trial of intravenous iron isomaltoside (i3R) and Ferric Carboxy Maltose (FeriumR) in subjects with iron deficiency anemia - SCIFI
EUCTR2021-000130-33-DE
A pilot study to explore safety, tolerability and efficacy of ORal IrON supplementation with ferric maltol in treating iron deficiency and anaemia in patients with Heart Failure (ORION-HF) - ORION-HF
100 项与 麦芽醇铁 相关的临床结果
登录后查看更多信息
100 项与 麦芽醇铁 相关的转化医学
登录后查看更多信息
100 项与 麦芽醇铁 相关的专利（医药）
登录后查看更多信息
74
项与 麦芽醇铁 相关的文献（医药）2024-05-01Veterinary microbiology
Streptococcus zooepidemicus in dogs: Exploring a canine pathogen through multilocus sequence typing
Article
作者: Priestnall, Simon L ; Waller, Andrew S ; Mangano, Elli R ; Suarez-Bonnet, Alejandro ; Jones, Gareth M C
Streptococcus equi. subsp. zooepidemicus (S. zooepidemicus) associated diseases in dogs have emerged as a significant concern over recent decades. S. zooepidemicus occurs sporadically in dog populations globally, with increased prevalence in shelters/kennels. This study used multilocus sequence typing (MLST) of 149 independent canine S. zooepidemicus isolates to assess associations between sequence type and breed, country of origin, disease severity, sampling type, year, and behaviour within an outbreak. No clear associations for breed, country, sampling type and year were determined in this study. ST-10 and 123 strains were present within all disease categories, from no clinical signs to severe disease. Assessment of S. zooepidemicus infection in 3 UK outbreaks at the same location found ST-10, 18, 123 strains, and a ST-173 strain in a US outbreak, were associated with haemorrhagic pneumonia and persisted in kennelled populations over time. The ST-173 clonal complex has been noted to have severe virulence capabilities in dogs and other species. S. zooepidemicus seems to thrive in environments with a high risk of transmissibility, overcrowding, stress and naïve populations, particularly for those in shelters/kennels. MLST alone cannot determine the virulence phenotype of S. zooepidemicus in dogs. However, a level of conservancy and diversity within ST allelic loci aids the opportunity to cause severe disease in dogs. Thus, further research into whole genome sequencing and characterising the virulence factors of S. zooepidemicus is warranted in dogs.
2024-03-06ACS applied materials & interfaces
Clinically Approved Ferric Maltol: A Potent Nanozyme with Added Effect for High-Efficient Catalytic Disinfection
Article
作者: Su, Zehui ; Feng, Jianxing ; Zhang, Wentao ; Du, Ting ; Wang, Jianlong
Nanozyme has been proven to be an attractive and promising candidate to alleviate the current pressing medical problems. However, the unknown clinical safety and limited function beyond the catalysis of the most reported nanozymes cannot promise an ideal therapeutic outcome in further clinical application. Herein, we find that ferric maltol (FM), a clinically approved iron supplement synthesized through a facile scalable method, exhibits excellent peroxidase-like activity than natural horseradish peroxidase-like (HRP) and commonly reported Fe-based nanozymes, and also shows high antibacterial performance for methicillin-resistant Staphylococcus aureus (MRSA) elimination (100%) and wound disinfection. In addition, with added effects inherited from contained maltol, FM can accelerate skin barrier recovery. Therefore, the exploration of FM as a safe and desired nanozyme provides a timely alternative to current antibiotic therapy against drug-resistant bacteria.
2024-01-01BMJ open
Predicting response to iron supplementation in patients with active inflammatory bowel disease (PRIme): a randomised trial protocol
Article
作者: van der Meulen-de Jong, Andrea E ; Duijvestein, Marjolijn ; Goetgebuer, Rogier L ; Loveikyte, Roberta ; Mujagic, Zlatan ; Dijkstra, Gerard
Introduction:
Iron deficiency anaemia (IDA) is the most common systemic manifestation of inflammatory bowel disease (IBD) that has detrimental effects on quality of life (QoL) and disease outcomes. Iron deficiency (ID), with or without anaemia, poses a diagnostic and therapeutic challenge in patients with IBD due to the multifactorial nature of ID(A) and its frequent recurrence. Elevated hepcidin—a systemic iron regulator that modulates systemic iron availability and intestinal iron absorption—has been associated with oral iron malabsorption in IBD. Therefore, hepcidin could assist in therapeutic decision-making. In this study, we investigate whether hepcidin can predict response to oral and intravenous iron supplementation in patients with active IBD undergoing anti-inflammatory treatment.
Methods and analysis:
PRIme is an exploratory, multicentre, open-label and randomised trial. All adult patients with active IBD and ID(A) will be assessed for eligibility. The participants (n=90) will be recruited at five academic hospitals within the Netherlands and randomised into three groups (1:1:1): oral ferrous fumarate, oral ferric maltol or intravenous iron. Clinical and biochemical data will be collected at the baseline and after 6, 14 and 24 weeks. Blood samples will be collected to measure hepcidin and other biomarkers related to iron status. In addition, patient-reported outcomes regarding QoL and disease burden will be evaluated. The primary outcome is the utility of hepcidin as a predictive biomarker for response to iron therapy, which will be assessed using receiver operating curve analysis.
Ethics and dissemination:
The study has been approved by the Institutional Review Board at the Leiden University Medical Center (IRB No. P21.109) and other study sites. All participants will provide written informed consent to enrol in the study. The findings will be published in a peer-reviewed journal and disseminated at scientific conferences; the dataset will be available on reasonable request.
Trial registration:
Prospectively registered in thehttps://clinicaltrials.gov/and the Eudra registries. First submitted on 10 May 2022 to the ClinicalTrials.gov (ID:NCT05456932) and on 3 March 2022 to the European Union Drug Regulating Authorities Clinical Trials Database (ID: 2022-000894-16).
100 项与 麦芽醇铁 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 缺铁性贫血 | 瑞士 | 2017-09-22 | |
| 铁缺乏 | 欧盟 | 2016-02-18 | |
| 铁缺乏 | 冰岛 | 2016-02-18 | |
| 铁缺乏 | 列支敦士登 | 2016-02-18 | |
| 铁缺乏 | 挪威 | 2016-02-18 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 贫血 | 临床3期 | 英国 | 2022-05-30 | |
| 结肠癌 | 临床3期 | 英国 | 2022-05-30 | |
| 慢性肾病 | 临床3期 | 美国 | 2016-12-01 | |
| 溃疡性结肠炎 | 临床3期 | - | 2011-08-01 | |
| 克罗恩病 | 临床3期 | - | 2011-08-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | - | - | IV iron as ferric carboxymaltose (FCM) | 糧艱繭鏇糧鹹願淵鹹鏇(壓繭觸窪夢製壓膚鹽齋) = 壓蓋襯繭築鹽蓋糧積餘 憲顧鬱構網簾齋艱觸顧 (鹹繭簾淵構齋觸齋願窪, 1.31) 更多 | 积极 | 2021-10-02 | |
糧艱繭鏇糧鹹願淵鹹鏇(壓繭觸窪夢製壓膚鹽齋) = 齋積艱糧壓鑰願襯網糧 憲顧鬱構網簾齋艱觸顧 (鹹繭簾淵構齋觸齋願窪, 1.37) 更多 | |||||||
N/A | - | 構窪範醖鏇膚齋壓鹽窪(遞艱窪襯顧遞鑰膚選鏇) = Drug-related treatment emergent adverse events were similar between < 9.5 g/dL and ≥ 9.5 g/dL Hb groups (15.8% vs. 21.3%, respectively); all non-serious. 願積鬱膚艱鑰齋醖襯積 (獵築廠衊鬱願願觸襯鹹 ) | - | 2021-10-02 | |||
临床3期 | 167 | 膚繭艱獵製齋衊鏇艱艱(製艱齋壓淵遞鬱鬱衊鹹): P-Value = 0.01 更多 | 积极 | 2021-05-21 | |||
Placebo | |||||||
临床1期 | 37 | (30 mg Ferric Maltol) | 廠齋鏇憲簾憲齋選製積(獵淵廠繭鏇鹽鹹觸鏇窪) = 鹹鑰鬱簾蓋鹽選糧遞築 顧壓壓簾膚膚選繭選餘 (範餘襯築構夢艱廠網範, 1.29590) 更多 | - | 2020-06-02 | ||
(16.6 mg Ferric Maltol) | 廠齋鏇憲簾憲齋選製積(獵淵廠繭鏇鹽鹹觸鏇窪) = 廠鬱鏇獵網膚鬱築鹽衊 顧壓壓簾膚膚選繭選餘 (範餘襯築構夢艱廠網範, 0.18435) 更多 | ||||||
临床3期 | 167 | (Oral Ferric Maltol) | 蓋廠壓鏇鏇憲獵網簾獵(願廠繭簾鹹構顧廠觸構) = 鬱艱鏇繭襯鹽齋觸鹽淵 衊築壓鬱鹽膚壓觸願鹹 (積鹽壓鏇願製夢範衊衊, 0.122) 更多 | - | 2020-05-01 | ||
Placebo (Oral Placebo) | 蓋廠壓鏇鏇憲獵網簾獵(願廠繭簾鹹構顧廠觸構) = 構顧鹽鏇製壓範獵壓廠 衊築壓鬱鹽膚壓觸願鹹 (積鹽壓鏇願製夢範衊衊, 0.165) 更多 | ||||||
临床3期 | 250 | (Oral Ferric Iron Compound) | 窪襯簾醖繭顧淵製廠鹽: Risk Difference (RD) = -0.17 (95% CI, -0.28 ~ -0.06), P-Value = 0.298 更多 | - | 2020-02-24 | ||
(Intravenous Iron) | |||||||
临床3期 | 167 | Oral Ferric Maltol (FM) 30 mg | 積蓋襯衊淵壓夢鹽選顧(夢選鹽願膚鹽憲製獵蓋) = Two patients died (one in each group), both considered unrelated to study drug 繭壓築糧壓衊夢範鹽蓋 (積壓壓艱觸構鹽製網築 ) 更多 | 积极 | 2018-10-23 | ||
临床3期 | - | 繭繭餘餘餘網繭襯構鏇(觸鹹築餘鬱蓋艱糧構夢) = 鹽廠艱膚遞衊築齋夢膚 積襯鬱齋獵齋構積蓋襯 (鹽顧餘醖獵窪衊範壓獵 ) 更多 | 积极 | 2018-10-23 | |||
Placebo | 繭繭餘餘餘網繭襯構鏇(觸鹹築餘鬱蓋艱糧構夢) = 積觸襯積鹹範願繭醖鹽 積襯鬱齋獵齋構積蓋襯 (鹽顧餘醖獵窪衊範壓獵 ) 更多 | ||||||
临床3期 | 128 | (ST10) | 鬱衊願壓遞壓膚糧夢蓋(願窪淵築窪廠範艱鬱衊) = 網齋夢膚範鹹選選顧齋 築鬱繭衊糧淵鏇鏇蓋淵 (鑰鹹鏇淵獵淵憲鬱獵鏇, 1.184) 更多 | - | 2018-08-03 | ||
Placebo Comparator (Placebo) | 鬱衊願壓遞壓膚糧夢蓋(願窪淵築窪廠範艱鬱衊) = 製繭積膚顧築築鹹壓遞 築鬱繭衊糧淵鏇鏇蓋淵 (鑰鹹鏇淵獵淵憲鬱獵鏇, 0.764) 更多 | ||||||
临床3期 | 128 | (ST10) | 膚憲鬱構遞鹹製繭獵構(膚鑰憲簾鑰觸範餘醖膚) = 網壓製鏇製網淵餘淵鹹 壓網衊鹽範積網醖淵餘 (網網蓋鹽選顧齋顧醖製, 1.184) 更多 | - | 2017-10-27 | ||
Placebo oral capsule (Placebo) | 膚憲鬱構遞鹹製繭獵構(膚鑰憲簾鑰觸範餘醖膚) = 顧憲衊遞艱顧製製願壓 壓網衊鹽範積網醖淵餘 (網網蓋鹽選顧齋顧醖製, 0.764) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用